Chardan Capital Reiterates Buy Rating on Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Context

Arrowhead Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $88.70 with a market capitalization of $8.9B. The stock has gained 358.3% over the past 52 weeks.

Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Arrowhead Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Arrowhead Pharmaceuticals, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 22, 2026	Chardan Capital	Buy	N/A
Jul 17, 2026	JP Morgan	Overweight	N/A
Jul 14, 2026	Stifel	Buy	N/A
Jul 01, 2026	HC Wainwright & Co.	Buy	N/A
Jun 30, 2026	Chardan Capital	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View ARWR Stock Page